26 October 2026 · 4 min
Glaucoma eye drops, or not: what five and six years of trials found
Two UK trials started patients on something other than glaucoma eye drops. Both found less field loss, and patients who could not feel the difference.
Class IIa medical device in development
Vision loss should not be accepted as inevitable.
We develop photonic systems that safely stimulate retinal cells and support repair processes, helping to preserve central vision and independence for people living with dry macular degeneration.
- Indication
- Early and intermediate dry AMD
- Session
- 12 minutes, binocular
- Setting
- Community optometry, domiciliary optometry and hospital clinics
The unmet need
A silent epidemic, treated by waiting.
90% of people with age-related macular degeneration have the dry form. For most of them the standard of care is still monitoring, lifestyle advice and supplements, while their central vision declines.
- people worldwide living with age-related macular degeneration
- 200Mpeople worldwide living with age-related macular degeneration
- of AMD is the dry form, with limited approved treatment options
- 90%of AMD is the dry form, with limited approved treatment options
- people progress to severe vision loss from AMD each year
- >500kpeople progress to severe vision loss from AMD each year
- increase in AMD prevalence expected between 2020 and 2040
- +47%increase in AMD prevalence expected between 2020 and 2040
- higher risk of cognitive decline and dementia with vision impairment
- ×2higher risk of cognitive decline and dementia with vision impairment
- vision loss ranks among the three most feared health outcomes
- Top 3vision loss ranks among the three most feared health outcomes
People living with AMD worldwide
Each figure is two million people. The dark centre of every head is the central vision that dry AMD takes.
196million people living with AMD
2020published
- Living with AMD in 2020
- Added by 2040: 92 million
20202040
The figures behind this chart
| Year | People with AMD |
|---|---|
| 2020 | 196 million |
| 2040 | 288 million |
Source: Wong et al., The Lancet Global Health, 2014. Years between the two published figures are a straight line between them.
£2.6bn
a year is what AMD-related sight loss costs the UK, of which £1.2 billion falls directly on healthcare and the rest on informal care, lost productivity and lost quality of life
Source: Fight for Sight, Time to Focus (2020), as cited in the Royal College of Ophthalmologists' AMD Commissioning Guidance, June 2021.
From observation to intervention
Stop monitoring. Start treating.
As diagnostic technology in community optometry has advanced, retinal disease is identified earlier than ever. Yet for millions of patients an early diagnosis is followed by “watch and wait”, because hospital-grade interventions do not scale to the community setting.
BioPhotonix exists to close that gap. By translating photobiomodulation into a regulated, portable medical platform, we give optometrists the means to intervene early, in the same room where the diagnosis was made.
The pathway today
- Diagnosis in community optometry
- Watch and wait
- Progressive decline
- Late referral
The pathway with Revolux
- Diagnosis in community optometry
- Eligibility screening
- Treatment in clinic
- Monitored response
- Independence preserved
Revolux
Revolux. Engineered by BioPhotonix.
Revolux is a binocular photobiomodulation system that actively stimulates compromised retinal cells and supports their repair, helping to preserve central vision in early and intermediate dry macular degeneration.
Each session takes twelve minutes. It fits a standard consulting room, needs no dedicated infrastructure, and turns an unmet patient need into a structured, evidence-led clinical pathway.
Treat early
Intervene when it matters most, in the years before irreversible vision loss occurs.
Any room, any time
A portable binocular design that fits standard consulting rooms. No dedicated space, no fixed installation.
Precision dosing
Unlike desktop systems, Revolux guarantees exact source-to-eye geometry for every patient, every time.
- ISO 13485Quality management system
- EU MDRClass IIa, CE-first strategy
- UKCAUK market conformity
- ISO 15004-2Ophthalmic optical safety
- ANSI Z80.36Light hazard protection
- IEC 60601-1Medical electrical safety
- ISO 10993Biocompatibility
For optometrists and ophthalmologists
Hospital-grade care, inside your consulting room.
Revolux integrates active dry AMD intervention into the workflows you already run, turning an unmet patient need into a scalable, high-value clinical service.
01
Beyond generic light therapy
Bespoke treatment protocols optimise retinal stimulation beyond generic or fixed photobiomodulation.
02
Continuous revenue
Repeatable treatment cycles generate sustainable recurring revenue that scales linearly with patient volume.
03
Integrated workflows
Therapy slots into existing clinical workflows without dedicated space or fixed infrastructure.
04
Intelligent insights
Integrated software simplifies clinical reporting and supports decisions, reducing administrative burden.
05
Consistent delivery
Continuous care models replace passive management, keeping patients engaged with therapy over time.
06
No upfront cost
A low-friction subscription model eliminates high upfront costs, so the service is profitable from the start.
Development roadmap
From concept to clinic.
Medical device development is a disciplined journey of risk reduction. Each stage below locks something down before the next begins.
- TRL 1–3Complete
Research and problem definition
Confirmed that the science of photobiomodulation is sound, and that existing delivery methods fail community use: handheld devices lack consistency, hospital consoles lack accessibility.
- ArchitectureComplete
Binocular platform selected
A headset-based architecture chosen to guarantee precise source-to-eye geometry and repeatable dosimetry, so every patient receives the intended dose whichever clinic they visit.
- TRL 4Complete
Lab validation
Functional prototypes fabricated with Med Design validated the ergonomic assumptions for adults over 50. Thermal limits, output stability and software logic tested.
- TRL 5In progress
Design freeze
Locking the hardware configuration: optical arrays, power subsystems and safety interlocks, under ISO 13485 quality standards, with optical engineering input from Fraunhofer and WideBlue.
- NextPlanned
Pilot clinical evaluation
Revolux moves out of the lab and into the hands of clinicians: the final step before scaling for regulatory approval.
- RegulatoryPlanned
CE and UKCA marking
Class IIa conformity under the EU MDR, then UKCA for the UK market, with third-party testing against the optical, electrical and biocompatibility standards.
- LaunchPlanned
Community deployment
Subscription rollout to community optometry, with clinician training, integrated reporting and post-market surveillance.
Leadership
Founded by a clinician who ran out of things to offer.
Adail is an optometrist and orthoptist with extensive clinical experience managing macular disease across both hospital ophthalmology pathways and community optometry settings.
His direct experience on the front lines of eye care revealed the limitations of existing treatments: hospital-bound technologies could not scale to meet the needs of the millions of patients managed in primary care. Adail founded BioPhotonix to engineer a solution that fits the reality of clinical practice: a device that is clinically rigorous, regulator-ready, and accessible enough to be deployed in every community clinic.
Latest insights
From the team.
26 October 2026 · 4 min
Acuity and microperimetry: why Europe refused a drug the US approved
The US approved pegcetacoplan for geographic atrophy on scans. Europe refused it: acuity, reading and microperimetry showed no benefit in two years.
19 October 2026 · 4 min
The number plate eye test is not a night-driving test
In young volunteers in glasses that cut acuity and contrast, a 6/12 cut-off caught 61% of plate failures near the cut-off, against 97% for blur alone.
Get in touch
Talk to BioPhotonix.
Whether you run a practice, treat retinal disease in hospital, or are looking at the company as an investor, we would like to hear from you.